Earnings History Data for PLIANT THERAPT (PLRX) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

PLIANT THERAPT

Pliant Therapeutics Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product consist PLN-74809 and PLN-1474 which are in clinical stage. Pliant Therapeutics Inc. is based in SAN FRANCISCO, Calif.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
11-05-2026	AH		PLRX	PLIANT THERAPT	77.00	-0.32	-0.36	0.00		1.18	-0.02 (-1.67%)	1.20	0.0 (0.00%)	1.09 - 1.95	252,821	350,000	4,221

11-03-2026	AH		PLRX	PLIANT THERAPT	81.00	-0.35	-0.42	0.00	Pliant Therapeutics GAAP EPS of -$0.38 in-line [3/11/2026 4:36 PM]	1.41	0.07 (5.64%)	1.30	-0.03 (-1.91%)	1.09 - 1.95	1,177,109	420,000	6,508
Pliant Therapeutics GAAP EPS of -$0.38 in-line [3/11/2026 4:36 PM]
03-03-2025	AH		PLRX	PLIANT THERAPT	198.00	-0.82	-0.99	0.00	Pliant Therapeutics GAAP EPS of -$0.82 beats by $0.17 [3/3/2025 5:05 PM]	1.40	0.02 (1.09%)	1.45	0.07 (5.07%)	1.28 - 16.81	3,558,476	4,320,000	123,899
Pliant dives 49% as it abandons phase 2 trial of bexotegrast for IPF [3/3/2025 11:07 AM] Pliant Therapeutics GAAP EPS of -$0.82 beats by $0.17 [3/3/2025 5:05 PM] Pliant downgraded at Stifel on bexotegrast trial discontinuation [3/4/2025 10:32 AM] Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results [2025-03-03 04:05PM] Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis [2025-03-03 09:27AM]
07-11-2024	PM		PLRX	Pliant Therapeutics	906.00	-0.95	-0.99	0.00	Pliant Therapeutics GAAP EPS of -$0.95 [11/8/2024 12:26 AM]	14.98	-0.21 (-1.38%)	16.00	0.81 (5.33%)	10.22 - 19.62	316,408	330,000	407
Pliant Therapeutics GAAP EPS of -$0.95 [11/8/2024 12:26 AM]
07-08-2024	AH		PLRX	Pliant Therapeutics	779.00	-0.92	-0.85	0.00	Pliant Therapeutics GAAP EPS of -$0.92 misses by $0.07 [8/7/2024 6:15 PM]	12.21	-0.33 (-2.67%)	12.54	0.0 (0.00%)	10.29 - 19.88	361,016	630,000	11,940
Pliant Therapeutics GAAP EPS of -$0.92 misses by $0.07 [8/7/2024 6:15 PM]
06-05-2024	AH		PLRX	Pliant Therapeutics	799.00	-0.78	-0.76	0.00	Pliant Therapeutics GAAP EPS of -$0.78 misses by $0.01 [5/6/2024 5:33 PM]	13.79	0.0 (0.00%)	14.09	0.30 (2.18%)	11.21 - 24.74	257,591	390,000	910
Pliant Therapeutics GAAP EPS of -$0.78 misses by $0.01 [5/6/2024 5:33 PM]
09-11-2023	AH		PLRX	Pliant Therapeutics	939.00	-0.70	-0.78	0.00	Pliant Therapeutics GAAP EPS of -$0.70 beats by $0.08 [11/9/2023 5:33 PM]	13.85	-0.35 (-2.50%)	14.20	0.0 (0.00%)	13.04 - 36.64	691,134	520,000	9,612
Pliant Therapeutics GAAP EPS of -$0.70 beats by $0.08 [11/9/2023 5:33 PM]
09-08-2023	AH		PLRX	Pliant Therapeutics	1,112	-0.70	-0.73	0.00	Pliant Therapeutics GAAP EPS of -$0.70 beats by $0.01, revenue of $0.25M misses by $0.65M [8/9/2023 5:53 PM]	18.77	0.59 (3.25%)	18.18	0.0 (0.00%)	16.42 - 36.64	571,222	900,000	8,587
Pliant Therapeutics GAAP EPS of -$0.70 beats by $0.01, revenue of $0.25M misses by $0.65M [8/9/2023 5:53 PM]
09-03-2023	AH	4:00 PM ET (Mar 9)	PLRX	Pliant Therapeutics	1,504	-0.72	-0.70	0.00	Pliant Therapeutics GAAP EPS of -$0.72 misses by $0.02, revenue of $1.97M beats by $0.8M [3/9/2023 5:59 PM]	27.90	-0.67 (-2.35%)	28.57	0.0 (0.00%)	3.96 - 36.64	621,623	440,000	821
Pliant Therapeutics GAAP EPS of -$0.72 misses by $0.02, revenue of $1.97M beats by $0.8M [3/9/2023 5:59 PM]
28-02-2022	AH		PLRX	Pliant Therapeutics	303.00	-0.68	-0.76	0.00	Pliant Therapeutics GAAP EPS of -$0.68 beats by $0.09, revenue of $2M misses by $0.14M [2/28/2022 5:31 PM]	9.91	0.95 (10.54%)	9.20	0.23 (2.56%)	8.20 - 42.29	115,497	150,000	1,100
Pliant Therapeutics GAAP EPS of -$0.68 beats by $0.09, revenue of $2M misses by $0.14M [2/28/2022 5:31 PM] Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results [Feb-28-22 04:05PM] Pliant Therapeutics Announces Positive Data from Expanded Phase 1b BAL Trial of PLN-74809 Demonstrated Suppression of TGF- Signaling in Healthy Volunteers [Feb-28-22 08:00AM] CORRECTION - Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results [Feb-28-22 07:43PM] Pliant Therapeutics, Inc. (PLRX) Reports Q4 Loss, Lags Revenue Estimates [Feb-28-22 05:55PM]
09-08-2021	AH	4:20 PM ET (Aug 9)	PLRX	Pliant Therapeutics, Inc.	804.00	-0.64	-0.64	0.00	Pliant Therapeutics EPS beats by $0.03, misses on revenue [8/9/2021 5:08 PM]	21.04	-2.13 (-9.19%)	23.00	-0.17 (-0.73%)	18.28 - 43.92	103,421	90,000	176
Pliant Therapeutics EPS beats by $0.03, misses on revenue [8/9/2021 5:08 PM] Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2021 Financial Results [Aug-09-21 04:05PM]
10-05-2021	AH	4:05 PM ET (May 10)	PLRX	Pliant Therapeutics, Inc.	1,138	-0.64	-0.59	0.00	Pliant Therapeutics EPS misses by $0.01, misses on revenue [5/10/2021 5:04 PM]	32.59	2.10 (6.89%)	30.49	0.0 (0.00%)	19.43 - 43.92	64,422	90,000	1,021
Pliant Therapeutics EPS misses by $0.01, misses on revenue [5/10/2021 5:04 PM] Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2021 Financial Results [May-10-21 04:21PM]
16-03-2021	AH		PLRX	Pliant Therapeutics, Inc.	1,350	-0.54	-0.61	0.00	Pliant Therapeutics EPS beats by $0.51, beats on revenue [3/16/2021 4:58 PM]	39.94	1.44 (3.74%)	38.50	-1.04 (-2.63%)	19.42 - 43.92	289,122	180,337	0
Pliant Therapeutics EPS beats by $0.51, beats on revenue [3/16/2021 4:58 PM] Pliant Therapeutics Announces Successful Completion of PLN-1474 Phase 1 Study and Development Transition to Global Pharmaceutical Partner [Mar-16-21 08:00AM] Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2020 Financial Results [Mar-16-21 04:05PM]